

ONLINE SUPPLEMENTARY MATERIAL

Supplementary Table 1. Sensitivity analysis of Child Ethnicity and NLE Risk and Specific Manifestations, multivariable models including Maternal Anti-La Antibody status in pregnancy (n=324)

Covariate	NLE OR (95%CI) p-value	Cardiac OR (95%CI) p-value	Cutaneous OR (95%CI) p-value	Hematologic OR (95%CI) p-value	Hepatic OR (95%CI) p-value	Neurologic OR (95%CI) p-value
Child Ethnicity (European referent): Non-European Mixed European – Non- European	1.23 (0.74-2.06) P=0.41 1.20 (0.65-2.33) P=0.57	0.58 (0.21-1.60) P=0.24 1.07 (0.32-3.54) P=0.90	1.86 (0.81-4.25) P=0.13 1.20 (0.37-3.83) P=0.75	1.32 (0.70-2.48) P=0.37 0.78 (0.33-1.84) P=0.57	1.06 (0.60-1.89) P=0.81 1.42 (0.69-2.91) P=0.32	0.44 (0.11-1.67) P=0.23 0.75 (0.13-4.05) P=0.73
Male Sex (Female referent)	0.72 (0.46-1.12) P=0.15	0.50 (0.20-1.25) P=0.14	1.02 (0.50-2.07) P=0.94	0.62 (0.36-1.08) P=0.09	0.55 (0.33-0.90) P=0.01	2.52 (0.74-8.57) P=0.13
Antimalarials in pregnancy	0.78 (0.46-1.31) P=0.34	0.83 (0.24-2.85) P=0.77	0.72 (0.30-1.67) P=0.44	0.83 (0.45-1.53) P=0.56	0.57 (0.31-1.03) P=0.06	1.62 (0.42-6.25) P=0.47
Maternal rheumatic disease	0.89 (0.51-1.55) P=0.68	0.26 (0.09-0.75) P=0.01	0.94 (0.40-2.20) P=0.89	2.25 (1.08-4.68) P=0.02	1.05 (0.58-1.92) P=0.85	1.03 (0.22-4.86) P=0.96
Maternal anti-La Antibody in pregnancy (Negative referent): Positive Missing	1.32 (0.74-2.34) P=0.33 1.06 (0.63-1.77) P=0.82	2.03 (0.61-6.72) P=0.24 2.47 (0.83-7.32) P=0.10	3.11 (1.35-7.27) P=0.008 1.06 (0.42-2.70) P=0.88	0.69 (0.34-1.40) P=0.31 0.72 (0.38-1.36) P=0.31	1.08 (0.57-2.04) P=0.79 1.02 (0.57-1.83) P=0.93	3.67 (0.87-15.37) P=0.07 1.14 (0.22-5.85) P=0.87

Multivariable models adjusted for sex, antimalarial use during pregnancy, maternal rheumatic disease status and maternal Anti-La antibody status in pregnancy. NLE: neonatal lupus erythematosus, OR: odds ratio, 95%CI: 95% confidence interval